Literature DB >> 24148151

Design, synthesis and bioevaluation of novel N-substituted-3,5-bis(arylidene)-4-piperidone derivatives as cytotoxic and antitumor agents with fluorescent properties.

Jufeng Sun1, Shuping Zhang, Chen Yu, Guige Hou, Xiaofan Zhang, Keke Li, Feng Zhao.   

Abstract

Ten new N-substituted-3,5-bis(arylidene)-4-piperidone derivatives (series 1 and 2) were synthesized and subsequently evaluated against human carcinoma cell lines SW1990, MIA PaCa-2, PG-BE1, NCI-H460, and SK-BR-3 for cytotoxic activity by the CCK-8 method, and their fluorescent properties were investigated as well. The compounds were confirmed to display greater cytotoxic activity to the neoplastic cells, and approximately 50% of the IC50 values were lower than 5 μm. In particular, compounds 1a, 1c, 1d, and 1e bearing 3-bromophenyl groups were revealed as the most active antitumor drug candidates and had the average IC50 values of 1.94, 1.11, 1.16, and 0.817 μm, respectively. Furthermore, their fluorescent properties were interesting and might contribute to the visualization of their distribution in tumor cells. Some possible reasons for the disparity between cytotoxic activity and fluorescent properties in the two series of compounds were explored. This study revealed high potential of these molecules for further development as fluorescent cytotoxic and antitumor agents.
© 2013 John Wiley & Sons A/S.

Entities:  

Keywords:  4-Piperidone; antitumor agents; cytotoxic activity; fluorescent properties

Mesh:

Substances:

Year:  2014        PMID: 24148151     DOI: 10.1111/cbdd.12254

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  1 in total

1.  Hydroxyl-substituted double Schiff-base condensed 4-piperidone/cyclohexanones as potential anticancer agents with biological evaluation.

Authors:  Lianshuang Zhang; Qin Chen; Guige Hou; Wei Zhao; Yun Hou
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.